Shots:
Osivax reported that the P-IIb (Asuniva) field efficacy trial of OVX836 (480 µg) vs PBO in 2,850 healthy adults aged 18–59yrs. in Europe did not meet its pre-specified 1EP of 50% vaccine efficacy (VE), with a VE point estimate of 24% (not statistically significant)
2EPs showed VE point estimates of 28% (CDC-defined influenza-like illness),…
